Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Meta has made a huge leap forward from typical chatbots to Muse, which is a…
East Zone won the 2026-27 Duleep Trophy after the final between East Zone and South…
India's CCTS (Carbon Credit Trading Scheme) has been given an approval by the UK to…
The state of Bihar is influenced heavily by many river systems like the Ganga, Son,…
Sheetal Devi of India created her mark in India in her impressive performance at the…
The Karnataka Cabinet has finalized the Karnataka Aerospace Policy 2026-31, in addition to a list…